Chief Technology Officer
Rick is currently the SVP of CMC at BridgeBio Pharma. Prior to joining BridgeBio, Rick served as VP of Pharmaceutical Development Services at WuXi STA, where he provided scientific leadership in formulation development and GMP manufacturing. From 2004 to 2015, Rick served as Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis. His responsibilities included all small molecule therapeutics across the Novartis portfolio. He also led and developed novel drug delivery technologies for small molecules and biologics. Rick has also led R&D groups at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb. Rick earned a Ph.D. in Chemistry from the University of Toronto and did a Post-Doctoral Fellowship at the University of California, Santa Barbara.
Co-founder & Chair, Scientific Advisory Board
Professor Javitt has devoted the past 30 years to the intersection of psychiatry and brain science. He was the first to identify the role of the NMDA receptor in modulating human thought processes in psycho-affective disorders. He is the author of more than 250 scientific publications and 10 patents in the field and is one of the most-widely cited authors in neuropsychiatry. His work has merited awards from the American Psychiatric Association and other leading organizations.
Regulatory & Patient Advocacy Advisor
Mr. Pines previously served as Associate Commissioner of the US Food and Drug Administration.
Dr. Morganroth received both his undergraduate degree and medical degree from the University of Michigan in Ann Arbor. He completed both his internship and residency in Internal Medicine at Yale University School of Medicine. He completed a Pulmonary and Critical Care Fellowship at the University of Colorado Health Sciences Center in Denver. He was an Assistant Professor at the University of Michigan in the Pulmonary and Critical Care Division from 1984-1990. At the University of Michigan, in addition to being active in patient care, he was also director of the Critical Care Medicine Unit, co-director of the critical care fellowship training program and carried out basic research on acute lung injury. Since 1990 he has served as the Director of the Research Department in the Pulmonary, Critical Care and Sleep Division of The Oregon Clinic. He is active in patient care, teaching and clinical research. He has been the principal investigator in many research studies and authored multiple journal articles and book chapters on topics related to respiratory disease.
Dr. Harry Peled is the Medical Director of Cardiology and Critical Care at Saint Jude Medical Center in Fullerton, California. In addition to being board-certified in cardiology and critical care, he is also board-certified in geriatrics, palliative care and neurocritical care. He graduated from the Albert Einstein College of Medicine with special distinction for research. He has authored works published In the New England Journal of Medicine, Chest, Annals of Internal Medicine, and many others. He also holds a Masters Degree in Bio Ethics and Health Policy from Loyola University.